The incidence of adrenal involvement in MEN1 syndrome has been reported between 9 and 45%, while the incidence of adrenocortical carcinoma (ACC) in MEN1 patients has been reported between 2.6 and 6%. In the literature data only unilateral development of ACCs in MEN1 patients has been reported. We report a 31 years-old female MEN1-patient, in whom hyperplasia of the parathyroid glands, prolactinoma, non functioning pancreatic endocrine carcinoma and functioning bilateral adrenal carcinomas were diagnosed. Interestingly, a not previously described in the literature data, novel germline mutation (p.E45V) in exon 2 of MEN1 gene, was detected. The association of exon 2 mutation of the MEN1 gene with bilateral adrenal carcinomas in MEN1 syndrome, should be further investigated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039620PMC
http://dx.doi.org/10.1186/1477-7819-9-6DOI Listing

Publication Analysis

Top Keywords

men1 gene
12
adrenocortical carcinoma
8
men1
8
mutation men1
8
men1 syndrome
8
men1 patients
8
patients reported
8
literature data
8
bilateral adrenal
8
adrenal carcinomas
8

Similar Publications

Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant disease with an estimated prevalence of 2 per 100,000. This disease is caused by a mutation in the tumor suppressor gene MEN1, which is located on chromosome 11 and codifies the menin protein. It is characterized by a predisposition of parathyroids, enteropancreatic, and anterior pituitary tumors, affecting the quality of life and lifespan of those who have the disease.

View Article and Find Full Text PDF
Article Synopsis
  • Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic disorder characterized by tumors in multiple endocrine glands, but some patients may lack the genetic markers typically associated with the condition.
  • A 56-year-old woman with a history of a macroprolactinoma, primary hyperparathyroidism, and a cortisol-producing adrenal adenoma was diagnosed with MEN1 despite being genotype-negative, raising concerns about the reliability of genetic testing.
  • The case highlights that genotype-negative MEN1 can involve serious complications and emphasizes the importance of recognizing clinical symptoms like glucose intolerance and tumor manifestations to avoid delayed diagnoses.
View Article and Find Full Text PDF

Alternative splicing generates isoform diversity in .

Endocr Oncol

January 2024

Department of Molecular Medicine and Pathology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Although the gene has a long-standing association with cancer, its mechanisms of action remain incompletely understood, acting both as a tumour suppressor in neuroendocrine tumours and as an oncogene in leukaemia. The best-characterised isoform of the encoded protein, MENIN, is the 610-amino acid MENIN isoform 2. We hypothesise that some of the complexity of biology can be attributed to a currently unappreciated contribution of different MENIN isoforms.

View Article and Find Full Text PDF

Genotype-based prognosis prediction for MEN1-Related pancreatic neuroendocrine tumors in Korean patients a single-center retrospective study.

Pancreatology

November 2024

Pancreatobiliary Cancer Center, Yonsei Cancer Center, Severance Hospital, Seoul, South Korea; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea. Electronic address:

Background: Pancreatic neuroendocrine tumors (PNETs) are the leading cause of death related to multiple endocrine neoplasia type 1 (MEN1). Previous studies have linked certain mutations in the MEN1 gene and loss of interactions with MENIN's functional partners to the mortality or aggressiveness of PNETs. This study aimed to evaluate the genotype-phenotype correlations of MEN1-related PNETs in Korean patients and to summarize the treatment outcomes comprehensively.

View Article and Find Full Text PDF

Multiple endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome characterized by endocrine tumors, typically from parathyroid, pancreatic, or anterior pituitary origin. In addition, benign cutaneous soft tissue tumors are prevalent in MEN1 patients. Although sarcomas have been reported in MEN1 patients it is unclear if these tumors should be considered as part of the MEN1 syndrome.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!